Next Article in Journal
Gene-Silencing-Induced Changes in Carbohydrate Conformation in Relation to Bioenergy Value and Carbohydrate Subfractions in Modeled Plant (Medicago sativa) with Down-Regulation of HB12 and TT8 Transcription Factors
Next Article in Special Issue
MicroRNA in Metabolic Re-Programming and Their Role in Tumorigenesis
Previous Article in Journal
Design of Acceptors with Suitable Frontier Molecular Orbitals to Match Donors via Substitutions on Perylene Diimide for Organic Solar Cells
Previous Article in Special Issue
Is the Efficiency of RNA Silencing Evolutionarily Regulated?
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(5), 718;

Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal
Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3004-517 Coimbra, Portugal
Author to whom correspondence should be addressed.
Academic Editor: Y-h. Taguchi
Received: 21 March 2016 / Revised: 6 May 2016 / Accepted: 6 May 2016 / Published: 13 May 2016
(This article belongs to the Special Issue MicroRNA Regulation)
Full-Text   |   PDF [273 KB, uploaded 13 May 2016]


Pancreatic cancer is an aggressive disease and the fourth most lethal cancer in developed countries. Despite all progress in medicine and in understanding the molecular mechanisms of carcinogenesis, pancreatic cancer still has a poor prognosis, the median survival after diagnosis being around 3 to 6 months and the survival rate of 5 years being less than 4%. For pancreatic ductal adenocarcinoma (PDAC), which represents more than 90% of new pancreatic cancer cases, the prognosis is worse than for the other cancers with a patient mortality of approximately 99%. Therefore, there is a pressing need for developing new and efficient therapeutic strategies for pancreatic cancer. In this regard, microRNAs not only have been seen as potential diagnostic and prognostic molecular markers but also as promising therapeutic agents. In this context, this review provides an examination of the most frequently deregulated microRNAs (miRNAs) in PDAC and their putative molecular targets involved in the signaling pathways of pancreatic
carcinogenesis. Additionally, it is presented a summary of gene therapy clinical trials involving miRNAs and it is illustrated the therapeutic potential associated to these small non-coding RNAs, for PDAC treatment. The facts presented here constitute a strong evidence of the remarkable opportunity associated to the application of microRNA-based therapeutic strategies as a novel approach for cancer therapy. View Full-Text
Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma; microRNAs; gene therapy; microRNA-based therapeutics pancreatic cancer; pancreatic ductal adenocarcinoma; microRNAs; gene therapy; microRNA-based therapeutics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Passadouro, M.; Faneca, H. Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy. Int. J. Mol. Sci. 2016, 17, 718.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top